Literature DB >> 16226537

Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas.

Michael D Onken1, Amy Y Lin, Lori A Worley, Robert Folberg, J William Harbour.   

Abstract

PURPOSE: To determine whether there is an association between gene expression profile and looping extravascular matrix patterns in primary uveal melanomas.
DESIGN: Laboratory investigation.
METHODS: Formalin-fixed, paraffin-embedded sections from 22 primary uveal melanomas that previously were analyzed by microarray gene expression profiling were stained for periodic acid-Schiff and scored in a masked fashion for the presence of looping extravascular matrix patterns.
RESULTS: A strong association was observed between looping patterns and the unfavorable class 2 molecular prognostic signature (P < .001).
CONCLUSIONS: Looping extravascular matrix patterns occur almost exclusively in class 2 uveal melanomas. This finding may provide new insights into the pathogenesis and management of uveal melanoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226537     DOI: 10.1016/j.ajo.2005.04.024

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  18 in total

Review 1.  Eye cancer: unique insights into oncogenesis: the Cogan Lecture.

Authors:  J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

2.  Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.

Authors:  Ahmad Al-Moujahed; Fotini Nicolaou; Katarzyna Brodowska; Thanos D Papakostas; Anna Marmalidou; Bruce R Ksander; Joan W Miller; Evangelos Gragoudas; Demetrios G Vavvas
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-29       Impact factor: 4.799

3.  Prognostic parameters in uveal melanoma and their association with BAP1 expression.

Authors:  T Huibertus van Essen; Sake I van Pelt; Mieke Versluis; Inge H G Bronkhorst; Sjoerd G van Duinen; Marina Marinkovic; Wilma G M Kroes; Claudia A L Ruivenkamp; Shruti Shukla; Annelies de Klein; Emine Kiliç; J William Harbour; Gregorius P M Luyten; Pieter A van der Velden; Rob M Verdijk; Martine J Jager
Journal:  Br J Ophthalmol       Date:  2014-08-21       Impact factor: 4.638

4.  Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens.

Authors:  Michael D Onken; Lori A Worley; Rosa M Dávila; Devron H Char; J William Harbour
Journal:  J Mol Diagn       Date:  2006-11       Impact factor: 5.568

5.  Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.

Authors:  ShriHari S Kadkol; Amy Y Lin; Vivian Barak; Inna Kalickman; Lu Leach; Klara Valyi-Nagy; Dibyen Majumdar; Suman Setty; Andrew J Maniotis; Robert Folberg; Jacob Pe'er
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

6.  A molecular revolution in uveal melanoma: implications for patient care and targeted therapy.

Authors:  J William Harbour; Daniel L Chao
Journal:  Ophthalmology       Date:  2014-01-28       Impact factor: 12.079

7.  Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas.

Authors:  Michael D Onken; Justis P Ehlers; Lori A Worley; Jun Makita; Yoshifumi Yokota; J William Harbour
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

8.  Ocular melanoma.

Authors:  Bertil E Damato; Sarah E Coupland
Journal:  Saudi J Ophthalmol       Date:  2012-04

Review 9.  An alternative hypothesis for observed mortality rates due to metastasis after treatment of choroidal melanomas of different sizes.

Authors:  James J Augsburger; Zélia M Corrêa; Nikolaos Trichopoulos
Journal:  Trans Am Ophthalmol Soc       Date:  2007

Review 10.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.